Partner Kevin Nelson was quoted on the Knowledge Ecology International’s urging of the National Institutes of Health (NIH) to leverage the Bayh-Dole Act in order to combat rising drug prices.
Like generic drugs in the 1980s, biosimilars today face a number of regulatory, legal, scientific, and public perception obstacles to continued growth.
This past November, the US Supreme Court heard oral arguments in a case that may dramatically affect how patents covering biologic drugs are litigated: Oil States Energy Services, LLC v Greene’s Energy Group, LLC.
This year brought us very significant changes in patent jurisprudence from the Supreme Court and Federal Circuit affecting Chemical & Life Sciences patent practice.
Twenty-two Arent Fox LLP practices have been recognized in the 2018 “Best Law Firms” rankings that are published annually by U.S. News & World Report and Best Lawyers.
Four Arent Fox attorneys participated in the ChIPs’ Women in Tech, Law, & Policy Global Summit, which seeks to help women network and advance their careers in technology, law, and policy.
Arent Fox LLP recently served as outside counsel to Rakuten Inc. in a multi-year partnership with the Golden State Warriors and the National Basketball Association.
Craig Gelfound has once again been honored by the Daily Journal as one of the Top Intellectual Property Lawyers in California, with 2017 marking his seventh consecutive year of this recognition.
On July 18, 2017, FDA held a public meeting to address efforts to ensure a balance between innovation in drug development and accelerating the access of the public to lower-cost alternatives to innovator drug therapies is maintained under the Drug Price Competition and Patent Term Restoration Act.
On June 21, the Food and Drug Administration announced a Drug Competition Action Plan in order to attempt to address ways that the agency’s rules have been, in the agency’s view, “gamed” to create obstacles that delay generic drug approvals to reduce generic competition.
The 2017 edition of Legal 500 US has rated 50 Arent Fox LLP attorneys as national leaders in their field. In addition, 17 of the firm’s practice areas were ranked among the best in the country. Legal 500 highlighted Arent Fox’s extensive capabilities across a number of areas of the law.
On May 30, 2017, the Supreme Court issued a landmark 8-0 decision holding that when a patentee sells one of its products, the patentee can no longer control that item through the patent laws.
This week, the Supreme Court unanimously rejected the Federal Circuit’s broad reading of the patent venue statute for domestic corporations in TC Heartland LLC v. Kraft Foods Group Brands LLC, No. 16-341, 2017 WL 2216934 (U.S. May 22, 2017).
On March 28, Arent Fox obtained a $2.2 million judgment in a patent infringement suit for its client Sabinsa Corporation. The case was brought in 2014 against Olive Lifesciences Pvt. Ltd. in the US District Court for the District of New Jersey.
Arent Fox Intellectual Property Associate Christopher H. Yaen penned a recent article published in Law360 on the recent practice of the Patent Trial and Appeal Board with respect to the rejection of claims for being in “improper Markush” format.
Arent Fox LLP Senior Policy Analyst Sen. Byron Dorgan and IP Partner Pamela Deese were featured guests on a March 12 episode of “What’s Working in Washington,” a weekly podcast focused on entrepreneurship, innovation, and policy.